Press Releases Chimeric Therapeutics Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:53 2024-05-31 am EDT			5-day change	1st Jan Change
0.018 ^AUD	-.--%		-21.74%	-48.57%

May. 22	Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4%	MT
May. 20	Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial	MT

Chimeric Therapeutics To Attend BIO International Convention	23-06-05	AQ
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial	23-06-04	AQ
Chimeric Therapeutics thrilled with ethics approval for brain cancer study	23-04-27	AQ
Chimeric Therapeutics : Application for quotation of securities - CHM	22-06-15	PU
Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies	22-04-11	GL
Chimeric Therapeutics : Appendix 2A	22-03-24	PU
Chimeric Therapeutics : Appendix 3B (amended)	22-03-07	PU
Chimeric Therapeutics : CORE NK Platform Phase 1 Clinical Data Presentation	22-03-06	PU
Chimeric Therapeutics : Appendix 3B (amended)	22-02-21	PU
Chimeric Therapeutics : Investor Presentation - Entitlement Offer	22-02-21	PU
Chimeric Therapeutics : Prospectus	22-02-21	PU
Chimeric Therapeutics : Appendix 3B	22-02-21	PU
Chimeric Therapeutics : Notification regarding unquoted securities - CHM	22-02-06	PU
Chimeric Therapeutics : Change of Director's Interest Notice - JC, CE & GM	21-12-14	PU
Chimeric Therapeutics : Application for quotation of securities - CHM	21-12-06	PU
Chimeric Therapeutics : Notification regarding unquoted securities - CHM	21-12-03	PU
Chimeric Therapeutics : Application for quotation of securities - CHM	21-12-03	PU
Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform	21-11-30	GL
Chimeric Therapeutics : Transformative Portfolio Expansion Presentation	21-11-30	PU
Chimeric Therapeutics : AGM Presentation	21-11-21	PU

No results for this search